Company CorMedix Inc.

CRMD

US21900C3088

Pharmaceuticals

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 01/07/2024 BST			5-day change	1st Jan Change
4.28 ^USD	-1.15%		+0.71%	+13.83%

05-28	CorMedix Shares Rise on Multiyear DefenCath Supply Deal	MT
05-28	CorMedix Inc. Announces Commercial Agreement with Top Tier Dialysis Provider	CI

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.

Number of employees: 83

Managers	Title	Age	Since
Joseph Todisco CEO	Chief Executive Officer	48	17/03/22
Mathew David DFI	Director of Finance/CFO	47	10/05/20
Tushar Mukherjee CTO	Chief Tech/Sci/R&D Officer	-	31/12/21
Beth Zelnick Kaufman LAW	General Counsel	63	12-11
Erin Mistry PRN	Corporate Officer/Principal	43	31/12/19
Frank Raffaele PRN	Corporate Officer/Principal	-	11/05/22
Donna Ucci PRN	Corporate Officer/Principal	-	11/05/22
Elizabeth Masson-Hurlburt PRN	Corporate Officer/Principal	45	28/02/18

Members of the board	Title	Age	Since
Myron Kaplan CHM	Chairman	79	26/04/16
Steven Lefkowitz DFI	Director of Finance/CFO	68	14/08/11
Alan Dunton BRD	Director/Board Member	70	28/02/19
Janet Dillione BRD	Director/Board Member	65	05/08/15
Joseph Todisco CEO	Chief Executive Officer	48	17/03/22
Gregory Duncan BRD	Director/Board Member	59	01/11/20
Robert Stewart BRD	Director/Board Member	56	12/04/23

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	54,959,270	54,430,199 ( 99.04 %)	0	99.04 %
Stock B	0	181,622	0	0

Name	Equities	%	Valuation
BlackRock Advisors LLC 6.083 %	3,342,956	6.083 %	18 M $
NOMURA HOLDINGS, INC. 5.370 %	2,951,439	5.370 %	16 M $
Vanguard Fiduciary Trust Co. 5.328 %	2,928,186	5.328 %	15 M $
Elliott Investment Management LP 2.821 %	1,550,523	2.821 %	8 M $
Geode Capital Management LLC 2.153 %	1,183,172	2.153 %	6 M $
STATE STREET CORPORATION 2.019 %	1,109,858	2.019 %	6 M $
Northern Trust Investments, Inc.(Investment Management) 0.7670 %	421,549	0.7670 %	2 M $
Joseph Todisco 0.5929 %	325,857	0.5929 %	2 M $
Renaissance Technologies LLC 0.4342 %	238,659	0.4342 %	1 M $
Susquehanna Securities LLC 0.3746 %	205,862	0.3746 %	1 M $

CorMedix, Inc.

300 Connell Drive Suite 4200

07922, Berkeley Heights

+908 517 9500

http://www.cormedix.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.28 USD

Average target price

13 USD

Spread / Average Target

+203.74%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
CORMEDIX INC.	+13.83%	238M
KYOWA KIRIN CO. LTD.	+16.03%	9.05B
SK BIOPHARMACEUTICALS CO., LTD.	-21.41%	4.4B
YUHAN CORPORATION	+21.80%	4.39B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+27.00%	3.94B
INDIVIOR PLC	+3.80%	2.1B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+12.87%	1.97B
BETTA PHARMACEUTICALS CO., LTD.	-34.72%	1.87B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-43.28%	1.61B

Specialty & Advanced Pharmaceuticals